Premium
Tumor Necrosis Factor Inhibitor Therapy for Rheumatoid Arthritis
Author(s) -
NAGUWA STANLEY M.
Publication year - 2005
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1361.115
Subject(s) - rheumatoid arthritis , medicine , tumor necrosis factor alpha , tumor necrosis factor α , immunopathology , immunology , immunotherapy , antirheumatic agents , necrosis , oncology , immune system
A bstract : The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.